Dolutegravir brings faster viral suppression in late pregnancy

Saye Khoo at AIDS 2018. Image credit: @UoLDolphin2
Carole Leach-Lemens
Published: 31 July 2018

Among 60 women presenting to routine antenatal clinics in Kampala, Uganda and Cape Town, South Africa with undiagnosed HIV in late pregnancy, viral load suppression was faster in those starting dolutegravir (DTG)- compared to efavirenz (EFV)-based antiretroviral therapy (ART). Dr Saye Khoo, on behalf of the DolPHIN-1 study group, presented data last week at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam.

Findings from this randomised controlled pilot study provide a potential means to reduce mother-to-child transmission at birth and during breastfeeding for women starting ART in late pregnancy.

Approximately 1.5 million women living with HIV become pregnant each year, 90% of whom live in resource-poor settings and who continue to present late (third trimester) in their pregnancy with untreated HIV. In South Africa around one in five pregnant women living with HIV start ART late. Starting ART in the third trimester is associated with failure to achieve viral suppression (< 50 copies/ml) by delivery, which is critical for prevention of mother-to-child transmission. Starting late is associated with a sevenfold increased risk of mother-to-child transmission, as well as a doubling of infant death in the first year.

Recommended first-line ART (EFV-based) takes a median of 84 days to reach viral suppression compared to 28 days for DTG-based ART.

The primary endpoint in this study was the pharmacokinetics (drug absorption, distribution, and excretion) of DTG in women and breastfed infants two weeks after delivery, while secondary endpoints included viral suppression at delivery as well as the safety and tolerability of DTG in pregnant women and their infants.

A scheduled interim analysis after the first 16 (eight on DTG) delivered, presented at CROI 2018, (poster #807) found DTG to be safe and confirmed that DTG exposure in the third trimester did not warrant a dose increase. The analysis also confirmed that mothers who start ART in late pregnancy are a vulnerable group who may have a higher rate of treatment failure.

In compliance with national guidelines (starting women on ART on the day diagnosed), standard of care EFV + two nucleoside reverse transcriptase inhibitors (NRTIs) began on referral with randomisation to continue standard of care or switch to DTG + two NRTIs a median of three (IQR:1-8) days later. In Uganda, the NRTIs comprised tenofovir and lamivudine and in South Africa, tenofovir and emtricitabine. DTG and EFV dosage was 50mg and 600mg daily, respectively.

Viral load was monitored at every visit. Intensive maternal pharmacokinetics sampling was done (0.5,1, 2, 3, 4, 6, 8 and 24 hours) after two weeks on DTG and two weeks after delivery, with paired sampling between maternal plasma and cord blood, breast milk and infant plasma. All infants were breastfed.

No significant differences before starting ART were seen between the DTG (n = 29) and the EFV (n = 31) arms in maternal age, length of pregnancy (median 31 weeks), weight, obstetric history, viral load (over 90% > 1000 copies/ml) or CD4 cell count (median 394 cells/mm3).

In just over a third of the women (9/28) DTG exposures in the third trimester were low with concentration levels (Ctrough) at or below the minimum effective concentration of 324ng/ml.

Significant infant exposure, possibly continuing through breastfeeding, was due to DTG transfer across the placenta (122%) and in breast milk (3%) together with delayed drug elimination.

At two weeks postpartum viral suppression (< 50 copies/ml) with DTG was significantly higher compared to EFV, 69% (20) and 39% (12), p = 0.02. Median time to viral suppression was approximately halved with DTG compared to EFV.

In the DTG arm, one mother had undetectable DTG concentrations with no viral load response, while another with DTG concentrations < 64 ng/ml had virological rebound.

There were no HIV transmissions.

The regimens were well tolerated.

Ninety-five per cent  (57) had normal healthy births with comparable infant outcomes. The median duration of pregnancy at birth was 38 weeks with a median infant weight of three kilogrammes.

Limitations include the small sample size, relatively short follow-up and prior EFV use in all mothers (subsequently randomised to DTG) starting ART, although the safety of DTG and EFV was comparable.

This pilot study showed a significantly greater proportion of mothers starting ART late in pregnancy achieved viral suppression with DTG-based, compared to EFV-based, regimens.

DolPHIN-2, comprising 250 women, a randomised comparison of starting ART in the third trimester with DTG compared to EFV, will further evaluate these findings.

Reference

Orrell C et al. DolPHIN-1: randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy. 22nd International AIDS Conference (AIDS 2018), Amsterdam, abstract THAB0307LB, July 2018.

View the abstract on the conference website.

Download the presentation slides from the conference website.

Watch the webcast of this session on YouTube.

NAM's news coverage of the 22nd International AIDS Conference has been supported by Gilead Sciences Europe Ltd. and ViiV Healthcare.



Official conference partners

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.